<DOC>
	<DOCNO>NCT02868099</DOCNO>
	<brief_summary>The objective evaluate efficacy safety romiplostim injection adlut subject persistent chronic primary immune thrombocytopenia ( ITP ) .</brief_summary>
	<brief_title>Efficacy Safety Romiplostim Adult Subjects With Persistent Chronic Immune Thrombocytopenia ( ITP )</brief_title>
	<detailed_description />
	<mesh_term>Thrombocytopenia</mesh_term>
	<mesh_term>Purpura , Thrombocytopenic , Idiopathic</mesh_term>
	<criteria>Diagnosed immune thrombocytopenia ( ITP ) least 6 month prior sign inform consent form ( ICF ) . Subject ≥ 18 year old signing ICF . Patients response relapse splenectomy . Or patient splenectomised response relapse least 1 prior treatment immune thrombocytopenia ( ITP ) . The mean 3 schedule platelet count take screening period must : &lt; 30 ×10^9/L , none &gt; 35×10^9/L . Any known history bone marrow stem cell disorder . Any abnormal bone marrow finding typical ITP . Any active malignancy . If prior history cancer basal cell carcinoma cervical carcinoma situ , treatment active disease within 5 year prior sign ICF.. Received hematopoietic growth factor ( e.g. , granulocyte colonystimulating factor , macrophage colonystimulating factor , erythropoietin , interleukin11 ) reason within 4 week prior sign ICF . Received myeloproliferative leukemia ( MPL ) stimulation product subject suspend recombinant human thrombopoietin ( rHuTPO ) injection 4 week sign ICF . Received antimalignancy agent ( e.g. , cyclophosphamide , 6mercaptopurine , vincristine , vinblastine , Interferonalfa ) reason within 8 week prior sign ICF . Received monoclonal antibody drug ( e.g. , rituximab ) reason within 14 week prior sign ICF . Less 4 week since end clinical trial therapeutic drug device prior sign ICF . Pregnant breastfeeding . In opinion principal investigator investigator , patient suitable participation trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>